NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
P/E ratio for NATCO Pharma Limited (NATCOPHARM.NS)
P/E ratio as of 2023: 12.56
According to NATCO Pharma Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.56. At the end of 2022 the company had a P/E ratio of 14.38.
P/E ratio history for NATCO Pharma Limited from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 12.56 |
| 2022 | 14.38 |
| 2021 | 81.12 |
| 2020 | 34.11 |
| 2019 | 19.96 |
| 2018 | 16.16 |
| 2017 | 19.65 |
| 2016 | 30.44 |
| 2015 | 45.33 |
| 2014 | 51.89 |
| 2013 | 24.83 |
| 2012 | 19.61 |
| 2011 | 17.24 |
| 2010 | 14.48 |
| 2009 | 7.70 |
| 2008 | 3.02 |
| 2007 | 5.91 |
| 2006 | 13.15 |
| 2005 | 15.27 |
| 2004 | 218.88 |